514 related articles for article (PubMed ID: 30115643)
1. Microfluidic Cell Culture Platforms to Capture Hepatic Physiology and Complex Cellular Interactions.
Bale SS; Borenstein JT
Drug Metab Dispos; 2018 Nov; 46(11):1638-1646. PubMed ID: 30115643
[TBL] [Abstract][Full Text] [Related]
2. A thermoplastic microfluidic microphysiological system to recapitulate hepatic function and multicellular interactions.
Bale SS; Manoppo A; Thompson R; Markoski A; Coppeta J; Cain B; Haroutunian N; Newlin V; Spencer A; Azizgolshani H; Lu M; Gosset J; Keegan P; Charest JL
Biotechnol Bioeng; 2019 Dec; 116(12):3409-3420. PubMed ID: 30963546
[TBL] [Abstract][Full Text] [Related]
3. Opportunities and challenges in the wider adoption of liver and interconnected microphysiological systems.
Hughes DJ; Kostrzewski T; Sceats EL
Exp Biol Med (Maywood); 2017 Oct; 242(16):1593-1604. PubMed ID: 28504617
[TBL] [Abstract][Full Text] [Related]
4. Pre-clinical and clinical investigations of metabolic zonation in liver diseases: The potential of microphysiology systems.
Soto-Gutierrez A; Gough A; Vernetti LA; Taylor DL; Monga SP
Exp Biol Med (Maywood); 2017 Oct; 242(16):1605-1616. PubMed ID: 28467181
[TBL] [Abstract][Full Text] [Related]
5. Biofabrication of a three-dimensional liver micro-organ as an in vitro drug metabolism model.
Chang R; Emami K; Wu H; Sun W
Biofabrication; 2010 Dec; 2(4):045004. PubMed ID: 21079286
[TBL] [Abstract][Full Text] [Related]
6. Characterization of rat or human hepatocytes cultured in microphysiological systems (MPS) to identify hepatotoxicity.
Chang SY; Voellinger JL; Van Ness KP; Chapron B; Shaffer RM; Neumann T; White CC; Kavanagh TJ; Kelly EJ; Eaton DL
Toxicol In Vitro; 2017 Apr; 40():170-183. PubMed ID: 28089783
[TBL] [Abstract][Full Text] [Related]
7. Organ-on-a-chip technology and microfluidic whole-body models for pharmacokinetic drug toxicity screening.
Lee JB; Sung JH
Biotechnol J; 2013 Nov; 8(11):1258-66. PubMed ID: 24038956
[TBL] [Abstract][Full Text] [Related]
8. Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism, and accumulation.
Rubiano A; Indapurkar A; Yokosawa R; Miedzik A; Rosenzweig B; Arefin A; Moulin CM; Dame K; Hartman N; Volpe DA; Matta MK; Hughes DJ; Strauss DG; Kostrzewski T; Ribeiro AJS
Clin Transl Sci; 2021 May; 14(3):1049-1061. PubMed ID: 33382907
[TBL] [Abstract][Full Text] [Related]
9. In vitro platforms for evaluating liver toxicity.
Bale SS; Vernetti L; Senutovitch N; Jindal R; Hegde M; Gough A; McCarty WJ; Bakan A; Bhushan A; Shun TY; Golberg I; DeBiasio R; Usta BO; Taylor DL; Yarmush ML
Exp Biol Med (Maywood); 2014 Sep; 239(9):1180-1191. PubMed ID: 24764241
[TBL] [Abstract][Full Text] [Related]
10. Novel 3D Culture Systems for Studies of Human Liver Function and Assessments of the Hepatotoxicity of Drugs and Drug Candidates.
Lauschke VM; Hendriks DF; Bell CC; Andersson TB; Ingelman-Sundberg M
Chem Res Toxicol; 2016 Dec; 29(12):1936-1955. PubMed ID: 27661221
[TBL] [Abstract][Full Text] [Related]
11. A high-throughput microfluidic microphysiological system (PREDICT-96) to recapitulate hepatocyte function in dynamic, re-circulating flow conditions.
Tan K; Keegan P; Rogers M; Lu M; Gosset JR; Charest J; Bale SS
Lab Chip; 2019 Apr; 19(9):1556-1566. PubMed ID: 30855604
[TBL] [Abstract][Full Text] [Related]
12. Next generation human skin constructs as advanced tools for drug development.
Abaci HE; Guo Z; Doucet Y; Jacków J; Christiano A
Exp Biol Med (Maywood); 2017 Nov; 242(17):1657-1668. PubMed ID: 28592171
[TBL] [Abstract][Full Text] [Related]
13. Microfluidics-based in vivo mimetic systems for the study of cellular biology.
Kim D; Wu X; Young AT; Haynes CL
Acc Chem Res; 2014 Apr; 47(4):1165-73. PubMed ID: 24555566
[TBL] [Abstract][Full Text] [Related]
14. A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity.
Kostadinova R; Boess F; Applegate D; Suter L; Weiser T; Singer T; Naughton B; Roth A
Toxicol Appl Pharmacol; 2013 Apr; 268(1):1-16. PubMed ID: 23352505
[TBL] [Abstract][Full Text] [Related]
15. A human liver microphysiology platform for investigating physiology, drug safety, and disease models.
Vernetti LA; Senutovitch N; Boltz R; DeBiasio R; Shun TY; Gough A; Taylor DL
Exp Biol Med (Maywood); 2016 Jan; 241(1):101-14. PubMed ID: 26202373
[TBL] [Abstract][Full Text] [Related]
16. Organ/body-on-a-chip based on microfluidic technology for drug discovery.
Kimura H; Sakai Y; Fujii T
Drug Metab Pharmacokinet; 2018 Feb; 33(1):43-48. PubMed ID: 29175062
[TBL] [Abstract][Full Text] [Related]
17. Modeling Barrier Tissues In Vitro: Methods, Achievements, and Challenges.
Sakolish CM; Esch MB; Hickman JJ; Shuler ML; Mahler GJ
EBioMedicine; 2016 Mar; 5():30-9. PubMed ID: 27077109
[TBL] [Abstract][Full Text] [Related]
18. Fitting tissue chips and microphysiological systems into the grand scheme of medicine, biology, pharmacology, and toxicology.
Watson DE; Hunziker R; Wikswo JP
Exp Biol Med (Maywood); 2017 Oct; 242(16):1559-1572. PubMed ID: 29065799
[TBL] [Abstract][Full Text] [Related]
19. Establishing quasi-steady state operations of microphysiological systems (MPS) using tissue-specific metabolic dependencies.
Maass C; Dallas M; LaBarge ME; Shockley M; Valdez J; Geishecker E; Stokes CL; Griffith LG; Cirit M
Sci Rep; 2018 May; 8(1):8015. PubMed ID: 29789564
[TBL] [Abstract][Full Text] [Related]
20. Microengineered Organ-on-a-chip Platforms towards Personalized Medicine.
Kankala RK; Wang SB; Chen AZ
Curr Pharm Des; 2018; 24(45):5354-5366. PubMed ID: 30799783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
